The disclosure features a human milk cream composition as well as methods of making a human milk cream composition and using a human milk cream composition. In particular, the disclosure features a method of using a human milk cream composition to raise the caloric content of human milk.

The invention relates to the Proline-Rich Polypeptide complex (PRP) derived from the mammalian colostrum for use in the treatment of the disorders and conditions related to the alterations of the Brain-Derived Neurotrophic Factor level as well as modulation thereof, particularly disorders and conditions wherein therapeutic strategy is based on the increasing of the BDNF concentration in blood. The PRP complex is postulated to be used for nutrition of adults, young children/babies and infants to promote and preserve the proper development and function of both immune and nervous system. PRPs may be used for supplementation of modified milk and infant milk formulae to make it closer to breast milk.

The present invention provides novel oral dosage comprising lyophilized mammalian (human) milk and optionally a physiologically acceptable excipient or carrier, and their use for improvement of mammalian (human) health. Also provided a novel process for preparing lyophilized mammalian milk with desired nutritional and cellular content, initially freezing raw milk obtained from a mammalian source, forming a layer of a predefined thickness from the frozen milk at a temperature from −4° C. to −80° C., and drying the formed layer at a temperature from −20° C. to +60° C. at a pressure from 5 micron Hg to atmospheric pressure to provide the lyophilized human milk. The process optionally comprises comprising treating said lyophilized milk via flash supercritical CO.sub.2 treatment comprising soaking said lyophilized milk with supercritical CO.sub.2

There is provided herein a composition for improving one or more health conditions comprising at least one keratin compound and beta-lactoglobulin (LGB) in a ratio of 1:1 to 1:5.

The invention relates to a process for the purification of a neutral human milk oligosaccharide (HMO) from a fermentation broth, the process comprising the steps of: (i) separating biomass from the fermentation broth to provide a crude solution; (ii) treating the crude solution with: (a) a cation-exchange material; (b) an anion-exchange material; and (c) a cation-exchange adsorbent resin; thereby obtaining a purified solution containing the neutral human milk oligosaccharide. Further, the invention relates to a process for fermentatively producing HMO in a fermentation broth and purifying the HMO from the broth.

The present disclosure relates to human milk compositions and methods of making and using the same. In particular, the disclosure features methods of using human milk compositions to feed subjects before and/or after surgery or medical operations and that are useful in promoting recovery.

Concentrating nutrients in breast milk may be achieved using an apparatus comprising a first sheet of material comprising a forward osmotic membrane, a second sheet of material sealed to the first sheet of material about a common outer perimeter thereof, the first sheet of material arranged so that water can traverse the forward osmotic membrane to an interior of the first and second sheets, and a dry carbohydrate within the interior of the first and second sheets exhibiting an osmotic draw property to draw water from un-concentrated, expressed human milk to form concentrated human milk. After a predetermined time, or upon the milk remaining after drawing of water through the membrane being a desired amount, the water draw can end.

This specification relates to preparing a purified human milk oligosaccharide (HMO) from an HMO solution by a process comprising nanofiltration, as well as processes for making foods, dietary supplements, medicines and infant formulas comprising a purified HMO. This specification also relates to purified HMOs and foods, dietary supplements, medicines and infant formulas prepared by processes disclosed in this specification.

The application relates to a method for treating a patient with irritable bowel syndrome (IBS), the method comprising administering to the patient one or more neutral human milk oligosaccharides (HMOs) selected from 2′-fucosyllactose (2′-FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N-fucopentaose I, lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), and combinations thereof.

A method of enhancing vaccine efficacy, treating or preventing an allergy, or treating or preventing an autoimmune disease in an animal can comprise administering to the animal a composition comprising colostrum.